Steph Leathers: I had the privilege of touring the Translational Research Institute
Steph Leathers, Managing Director ANZ at ghd, shared a post on LinkedIn:
“One of the most eye-opening and compelling days on the job in a long time. I recently had the privilege of touring the Translational Research Institute and speaking directly with NBCF-funded researchers, including the undeniably inspiring Professor Joy Wolfram, PhD and hearing from Associate Professor Cleola Anderiesz, CEO of the National Breast Cancer Foundation.
The mission was always clear to me but this experience really brought home just how powerful and purposeful their work is; with real progress being made toward a vision of Zero Deaths from breast cancer.
At ghd we’ve proudly supported National Breast Cancer Foundation, Inc. for 21 years through our annual Pink campaign. Together, we’ve contributed millions to breast cancer research, proudly as a diamond partner alongside David Jones, Estée Lauder and Professionals Real Estate. Each year, our iconic pink collection reminds women to self-check as part of their everyday beauty rituals. It’s more than just a campaign. It’s a catalyst for early detection – and early detection saves lives.
Since 1994, the death rate from breast cancer in Australia has reduced by over 40%, with survival rates rising from 76% to 92%. A powerful testament to the impact of research and the work that nbcf is doing to educate on early detection, prevention and new treatments. However, what I also learnt was that with this incredible progress comes the risk of assuming the hard work is done.
- Unfortunately, diagnoses have increased by a huge 21% over the last decade, especially in young women.
- Australia has the highest rate of diagnosis in the world.
- One in three women who are diagnosed will be under 40 years of age.
Truly sobering facts that hit home very hard for me as I walked the halls, thinking about some really special young, healthy women in my life who’s world was rocked by breast cancer (no family history, no warning signs) yet are here with us , in remission and living full lives thanks to this progress.
So more than ever, accelerated, diverse, and future-focused research strategies are key. And I’m more energised than ever to to play our part.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023